Lonza Group (LO31) Stock Overview
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
LO31 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 4.96 |
| 52 Week High | CHF 6.20 |
| 52 Week Low | CHF 4.68 |
| Beta | 0.82 |
| 1 Month Change | -5.52% |
| 3 Month Change | -7.29% |
| 1 Year Change | -18.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| LO31 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.2% | 8.6% | 0.6% |
| 1Y | -18.7% | -12.1% | 0.2% |
Return vs Industry: LO31 underperformed the German Life Sciences industry which returned -16.3% over the past year.
Return vs Market: LO31 underperformed the German Market which returned -0.1% over the past year.
Price Volatility
| LO31 volatility | |
|---|---|
| LO31 Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: LO31 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LO31's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 20,000 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.
Lonza Group AG Fundamentals Summary
| LO31 fundamental statistics | |
|---|---|
| Market cap | €37.76b |
| Earnings (TTM) | €995.29m |
| Revenue (TTM) | €7.15b |
Is LO31 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LO31 income statement (TTM) | |
|---|---|
| Revenue | CHF 6.53b |
| Cost of Revenue | CHF 4.18b |
| Gross Profit | CHF 2.35b |
| Other Expenses | CHF 1.44b |
| Earnings | CHF 909.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 22, 2026
| Earnings per share (EPS) | 13.01 |
| Gross Margin | 35.97% |
| Net Profit Margin | 13.92% |
| Debt/Equity Ratio | 54.3% |
How did LO31 perform over the long term?
See historical performance and comparisonDividends
Does LO31 pay a reliable dividends?
See LO31 dividend history and benchmarks| Lonza Group dividend dates | |
|---|---|
| Ex Dividend Date | May 13 2026 |
| Dividend Pay Date | May 26 2026 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 4 days |
Does LO31 pay a reliable dividends?
See LO31 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 05:12 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lonza Group AG is covered by 52 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Sebastian Bray | Berenberg |